#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17192	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2435	854.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1655	1655	C	1080	C,G,A	1078,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29532	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4073	903.8	0	.	n	.	0	T695C	SNP	695	695	T	1285	1285	C	1175	C,G,T,A	1170,3,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29532	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4073	903.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1927	1927	A	1165	A,T,C	1163,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29532	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4073	903.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2561	2561	C	1076	C,A	1075,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29532	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4073	903.8	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3187	3187	T	1054	T,A	1052,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29532	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4073	903.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2635	2635	A	1058	A,G,C	1056,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2502	folP	852	852	100.0	folP.l15.c4.ctg.1	2008	154.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1217	1219	AGC	226;223;224	A,C;G,C;C,T	225,1;222,1;223,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5944	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	4003	184.9	1	SNP	p	S91F	0	.	.	271	273	TCC	908	910	TCC	225;224;222	T;C,T;C	225;223,1;222	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5944	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	4003	184.9	1	SNP	p	D95N	0	.	.	283	285	GAC	920	922	GAC	225;225;226	G;A,G,T,C;C	225;222,1,1,1;226	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5944	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	4003	184.9	1	SNP	p	D95G	0	.	.	283	285	GAC	920	922	GAC	225;225;226	G;A,G,T,C;C	225;222,1,1,1;226	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	2298	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1838	155.9	1	SNP	p	G45D	1	.	.	133	135	GAC	690	692	GAC	239;241;240	G,C;A;C	238,1;241;240	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1334	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c17.ctg.1	1563	106.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5886	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3510	209.2	1	SNP	p	D86N	0	.	.	256	258	GAC	870	872	GAC	266;265;265	G;A,G,C;C,A	266;263,1,1;264,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5886	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3510	209.2	1	SNP	p	S87W	0	.	.	259	261	AGT	873	875	AGT	265;265;267	A,C;G;T	264,1;265;267	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5886	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3510	209.2	1	SNP	p	S87R	0	.	.	259	261	AGT	873	875	AGT	265;265;267	A,C;G;T	264,1;265;267	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5886	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3510	209.2	1	SNP	p	S87I	0	.	.	259	261	AGT	873	875	AGT	265;265;267	A,C;G;T	264,1;265;267	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5886	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3510	209.2	1	SNP	p	S88P	0	.	.	262	264	TCC	876	878	TCC	267;266;264	T,C;C;C,G	265,2;266;262,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4846	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3229	187.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1832	1834	GGC	279;278;277	G;G;C	279;278;277	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4434	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3003	184.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1593	1595	GCA	251;252;247	G;C,G;A	251;251,1;247	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4434	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3003	184.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1596	1598	ATC	245;243;241	A,C;T;C,A	244,1;243;240,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4434	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3003	184.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1608	1610	GTG	235;235;237	G;T;G	235;235;237	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4434	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3003	184.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1608	1610	GTG	235;235;237	G;T;G	235;235;237	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4434	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3003	184.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2112	2114	ACC	246;246;244	A,T;C,A;C	244,1;245,1;244	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4434	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3003	184.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2166	2168	GCG	244;242;243	G,C;C;G	243,1;242;243	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4434	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3003	184.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2166	2168	GCG	244;242;243	G,C;C;G	243,1;242;243	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4434	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3003	184.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2289	2291	GGC	247;244;243	G,T;G,A;C	246,1;243,1;243	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4434	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3003	184.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2298	2300	GGC	244;245;243	G;G;C	244;245;243	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4434	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3003	184.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2316	2318	CCG	244;245;247	C,G;C;G,A	242,2;245;246,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6226	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3357	230.4	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1726	1728	CTG	256;257;254	C,G;T,C;G,C	255,1;256,1;252,2	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2864	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2295	155.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	742	742	C	219	C,G	218,1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	S271T	NONSYN	811	813	TCG	66	68	ACT	76;76;76	A;C;T	74;74;74	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	72	74	GAT	76;76;76	G;A,T;T	74;73,1;74	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	D274S	NONSYN	820	822	GAT	75	77	AGT	76;75;75	A;G;T	74;74;74	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	N277H	NONSYN	829	831	AAC	84	86	CAC	75;75;75	C;A;C	74;74;74	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	R307E	NONSYN	919	921	AGA	174	176	GAA	3;3;3	G;A;A	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	T311A	NONSYN	931	933	ACA	186	188	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	E312D	NONSYN	934	936	GAA	189	191	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	F314I	NONSYN	940	942	TTC	195	197	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	A316S	NONSYN	946	948	GCG	201	203	TCG	2;3;3	T;C;G	2;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	V318A	NONSYN	952	954	GTC	207	209	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	G319S	NONSYN	955	957	GGC	210	212	AGC	3;3;3	A;G;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	G320A	NONSYN	958	960	GGT	213	215	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	334	porB1a	984	239	90.38	porB1a.l15.c4.ctg.3	409	34.5	0	.	p	.	0	G322V	NONSYN	964	966	GGT	219	221	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	G38E	NONSYN	112	114	GGA	602	604	GAA	294;295;293	G;A,T,C;A	294;292,1,1;293	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	S46G	NONSYN	136	138	AGC	626	628	GGC	291;287;287	G;G,T;C,A	291;286,1;286,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	632	634	GGA	293;289;292	G;G;A	293;289;292	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	T87A	NONSYN	259	261	ACT	749	751	GCT	261;257;257	G;C;T,C	261;257;256,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	755	757	AGC	255;254;253	A;G;C	255;254;253	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	847	848	CG	250;249	C,A;G	249,1;249	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	850	852	CAG	248;250;248	C;A,G;G	248;249,1;248	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	854	856	AAA	249;250;250	A;A;A,G	249;250;249,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	917	919	GAA	262;265;266	G,T;A,T;A	261,1;264,1;266	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	941	943	GCA	268;270;269	G;C,G;A,T	268;269,1;268,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1133	1135	ACT	260;260;264	A;C;T	260;260;264	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1142	1144	ATG	257;256;259	A;T,G;G	256;254,1;259	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1256	1258	GCA	220;219;215	G,C;C;A,T	219,1;219;214,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1259	1261	ACG	214;211;213	A;C;G	214;210;212	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	S258G	NONSYN	772	774	AGT	1262	1264	GGG	214;214;214	G,A;G,T;G	213,1;213,1;214	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1265	1267	GTT	219;222;223	G,T;T;T,G	218,1;222;222,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1325	1327	GTA	253;252;252	G;T;A	253;252;252	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1364	1366	ACT	266;267;270	A;C;T	266;267;270	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1370	1372	GAT	275;275;276	G;A,T;T	275;273,2;276	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1382	1384	CAC	286;288;290	C;A;C	286;288;290	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	1	SNP	p	G120K	1	.	.	358	360	AAG	847	849	CGG	250;249;248	C,A;G;G	249,1;249;248	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	1	SNP	p	D121N	0	.	.	361	363	GAC	850	853	CGC	248;248;249	C;G;C	248;248;249	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3056	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1674	221.2	1	SNP	p	A121D	1	.	.	361	363	GAC	850	853	CGC	248;248;249	C;G;C	248;248;249	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11308	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5311	265.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2208	2210	AAT	285;287;282	A;A;T	285;287;282	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1624	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1399	144.1	1	SNP	p	V57M	1	.	.	169	171	ATG	721	723	ATG	282;283;281	A;T,A;G	282;282,1;281	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
